TY - JOUR T1 - What is the optimal approach to the administration of intraperitoneal chemotherapy in ovarian cancer? JF - International Journal of Gynecologic Cancer JO - Int J Gynecol Cancer SP - 36 LP - 39 DO - 10.1111/j.1525-1438.2007.01103.x VL - 18 IS - Suppl 1 AU - M. Markman Y1 - 2008/02/01 UR - http://ijgc.bmj.com/content/18/Suppl_1/36.abstract N2 - Three well-designed and conducted randomized phase 3 trials have revealed that the intraperitoneal administration of cisplatin-based chemotherapy as primary treatment of small-volume residual advanced ovarian cancer improves both progression-free and overall survivals compared to an all intravenous cisplatin-based regimen. Based on very reasonable extrapolations from existing evidence-based data, a number of possible “options” can be proposed that use the intraperitoneal route for delivery of chemotherapy in this clinical setting ER -